ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1327

Decreased CD3-CD16CD56+ Natural Killer Cell Counts Are Associated with Disease Activity in Children with Orbital Myositis

Melissa R. Bussey1, Gabrielle A. Morgan2, Maria C. Amoruso2, Bahram Rahmani3 and Lauren M. Pachman4, 1Rheumatology, Division of Rheumatology, Loyola University Medical Center, Maywood, IL, 2Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Cure JM Myositis Center, Chicago, IL, 3Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Division of Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Eye disease, Myositis, natural killer (NK) cells and pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis (ACR)

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Orbital myositis (OM), an inflammatory disease affecting the extra-ocular muscles, typically presents in the third decade.  It more commonly affects females and is extremely rare in children.  Pediatric orbital inflammatory disorders account for 6-17% of the total orbital inflammatory disorders and OM specifically makes up about 8% of pediatric orbital inflammatory disease.  Because of the rarity of pediatric OM, many questions remain unanswered and specific laboratory markers of disease activity have not yet been identified, often resulting in a protracted course.  The objective of this study is to describe the course of OM in children and to identify potential reliable indicators of disease activity.

Methods:  After obtaining IRB approval, a retrospective review was performed of all patients with a diagnosis of OM presenting between 2006 and 2012 to the Cure-JM Program of Excellence of The Ann and Robert H. Lurie Children’s Hospital of Chicago.  Duration of untreated disease (DUD) was defined as time, in months, from onset of first symptoms to the date of the first medication.   Data for muscle enzymes, neopterin, and absolute level of CD3-CD56/16+ natural killer cells (NK) via flow cytometry were determined using standard methods in the Diagnostic Immunology Laboratory.  In addition, frozen sera were tested for immunoglobulin G 4 (IgG4) levels.

Results:  Of the 4 cases, 2 were female and all were Caucasian; the mean age of onset of the first symptom was 14.4±1.2 years, and the mean DUD was 0.28±0.26 months.  One child was seen after diagnosis, treatment, and resolution of disease.  At diagnosis/first visit of the 3 active children, muscle enzymes were tested and the means are as follows (n=3 except where noted): CPK: 97.3±44.2, aldolase: 8.5±2.8 (n=2), ALT: 13±2.8 (n=2), AST: 21.3±2.9, LDH: 176±52.4.  Their mean WBC was 10.4±1.3 (n=2), mean ESR 6±4, mean neopterin: 6.3±0.14 (n=2); mean Von Willebrand Factor Antigen:  133±14.1 (n=2). The mean for IgG4 was 87.7±66  (normal range=8-89 mg/dl).  The mean NK was 96.7±28.7 at diagnosis/first visit of the 3 active subjects (lower limit of normal =138) which increased to normal range 163±57.2 with resolution of active disease.  Computed tomography studies with contrast document involvement of left superior oblique, right superior oblique, left medial rectus, left lateral rectus, and right lateral rectus muscles in the 4 children.  Only 1 child had multiple orbital muscles involved concomitantly.  Treatment was initiated with high dose intermittent pulse methylprednisolone supplemented by daily oral prednisone (0.5 mg/kg) on non-IV day as well as methotrexate (n=2) and other steroid-sparing agents. Three of the 4 children returned to normal baseline after treatment completion. The fourth child was followed in another part of the country.

Conclusion:  OM does occur in children and disease activity was not associated with creatine kinase, aldolase, neopterin, sedimentation rate, or C reactive protein values, which typically remained within normal range.  In contrast, initially decreased absolute NK trended toward normal ranges as the inflammation improved.  We speculate that this lymphocyte subset may contribute to the inflammatory myopathy.


Disclosure:

M. R. Bussey,
None;

G. A. Morgan,
None;

M. C. Amoruso,
None;

B. Rahmani,
None;

L. M. Pachman,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/decreased-cd3-cd16cd56-natural-killer-cell-counts-are-associated-with-disease-activity-in-children-with-orbital-myositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology